Last checked at 1 Mar 2023 07:02
1 March 2023
ValiRx PLC ("ValiRx" or the "Company")
Investor Webinar
London, UK - ValiRx Plc (AIM: VAL), a life science company focusing on early-stage cancer therapeutics and women's health announces that Dr Suzanne Dilly will be presenting a live investor webinar on Wednesday, 8 March 2023 at 17:30 GMT.
The presentation will concentrate on the Company's strategy for its new tCRO operations, including progress on setting up the dedicated lab facilities in Nottingham.
The live webinar, which will be hosted by the Company's Joint Broker, Turner Pope Investments, is open to existing and prospective investors. There will be a Q&A session for investors after the presentation and questions can be submitted pre-event as part of the registration process. In addition, questions can be submitted during the live event.
To register for the webinar please visit the following link:
https://vimeo.com/webinars/events/d731558a-ecb5-40f0-9d7b-415902d2dd1f
The Directors of the Company take responsibility for this announcement.
For further information, please contact:
ValiRx plc Dr Suzanne Dilly, CEO
| Tel: +44 (0) 2476 796496 www.valirx.com Suzanne.Dilly@valirx.com |
V Formation (Public Relations)
Lucy Wharton - Senior PR Executive Sue Carr - Director | +44 (0) 115 787 0206 www.vformation.biz lucy@vformation.biz sue@vformation.biz |
Cenkos Securities Limited (Joint Broker) Russell Kerr/Michael Johnson (Sales) Callum Davidson/Giles Balleny (Corporate Finance) | Tel: +44 (0) 20 7397 8900 |
Turner Pope Investments (TPI) Limited (Joint Broker) James Pope / Andy Thacker | Tel: +44 (0) 20 3657 0050
|
This communication is a "Reach" announcement. Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained in this announcement is of a non-regulatory nature. Information required to be notified under the AIM Rules for Companies, Market Abuse Regulation or other regulation would be disseminated as an RNS regulatory announcement and not on RNS Reach.